In a report released today, David Lewis from Morgan Stanley maintained a Buy rating on Irhythm Technologies (IRTC), with a price target of $101. The company’s shares opened today at $90.10.
According to TipRanks.com, Lewis is a 5-star analyst with an average return of 11.0% and a 73.6% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Baxter International, and Edwards Lifesciences.
Currently, the analyst consensus on Irhythm Technologies is a Moderate Buy with an average price target of $98.25, which is a 9.0% upside from current levels. In a report released today, RBC Capital also maintained a Buy rating on the stock with a $109 price target.
See today’s analyst top recommended stocks >>
Based on Irhythm Technologies’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $10.24 million. In comparison, last year the company had a GAAP net loss of $11.15 million.
Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
iRhythm Technologies, Inc. is a commercial-stage digital healthcare company, which engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It also offers ZIO Service that has proprietary algorithms that distill data from millions of heartbeats into clinically actionable information.
